News | Cardiovascular Business | August 05, 2022

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline

Frank Van Hyfte, VP of Europe, the Middle East and Africa

Frank Van Hyfte, VP of Europe, the Middle East and Africa


August 5, 2022 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its commercial leadership team with the successful recruitment of two veterans of the medical device, surgical robotics and electrophysiology fields. 

Joining Stereotaxis are experienced commercial leaders with relevant and complementary expertise: 

  • Frank Van Hyfte is joining as Vice President of Europe, the Middle East and Africa. Van Hyfte spent over 15 years at Intuitive Surgical, the global leader in robotic surgery, between 2000 and 2016. While at Intuitive Surgical he rose in responsibility from the role of a Clinical Specialist to Director of Direct and Indirect Markets in Europe, the Middle East, India and Africa. He subsequently served in senior commercial leadership roles at Exact Imaging, EDAP TMS, and eCential Robotics. 
  • Tim Glynn is joining as Vice President, Market Development. Glynn most recently served as Vice President of Business and Market Development at Acutus Medical, an innovator in the electrophysiology mapping and ablation field. His responsibilities evolved from establishing commercial beachheads in Europe and the United States to managing product marketing, physician relationships and business partnerships. Prior to Acutus Medical, he served in senior marketing roles at Volcano Corporation, a leader in intravascular imaging for coronary and peripheral interventions.  

“We see in Stereotaxis the opportunity to build a preeminent robotic surgery company that positively transforms electrophysiology specifically and endovascular surgery more broadly,” said Van Hyfte and Glynn in a joint statement. “We join Stereotaxis at a fitting time as it establishes the product ecosystem that can allow for substantial commercial growth. We look forward to working together with the existing Stereotaxis team in building a highly impactful commercial organization.” 

The expertise of these new commercial leaders will complement Stereotaxis’ existing commercial leadership: Michael Tropea, Vice President of North America, and Casey Payne, Vice President of Asia Pacific. Tropea leads Stereotaxis’ commercial teams in North America and has been instrumental in establishing Stereotaxis’ capital sales processes, restarting capital adoption, and managing various marketing and business development initiatives. Payne leads Stereotaxis’ Asia Pacific and Global Training teams and has been central to the resurgence in commercial adoption in Asia and advancement of Stereotaxis’ strategic collaborations in China. 

“Stereotaxis has been energetically advancing a robust innovation pipeline that enables significant adoption of robotics across electrophysiology and endovascular surgery. In preparation for these product launches, we are assembling the right commercial leadership and establishing the commercial foundations for significant growth,” said David Fischel, Chairman and CEO. “We are excited to welcome Frank and Tim to the Stereotaxis team and look forward to their contributions as leaders in our efforts to pioneer endovascular robotics.”   

For more information: www.stereotaxis.com 


Related Content

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on ...

Home February 01, 2024
Home
Feature | Cardiovascular Business

Did you know that Diagnostic and Interventional Cardiology (DAIC) maintains more than 40 comparison charts of product ...

Home January 29, 2024
Home
News | Cardiovascular Business

January 24, 2024 — Medtronic announced the recent appointment of Simona Zannetti, MD, as the General Manager of its ...

Home January 24, 2024
Home
News | Cardiovascular Business

January 22, 2024 — The American College of Cardiology is again urging members of Congress to retroactively eliminate the ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — A physician-scientist from Massachusetts researching whether chemicals naturally occurring in foods ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 12, 2024 — The Heart Surgeon’s Cookbook is the brainchild of New York-based Cardiovascular and Thoracic Surgeon ...

Home January 12, 2024
Home
News | Cardiovascular Business

January 8, 2024 — GE HealthCare announced it has entered into an agreement to acquire MIM Software, a global provider of ...

Home January 08, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

As the Diagnostic and Interventional Cardiology (DAIC) team welcomes in the New Year, we also have taken a few moments ...

Home January 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a rundown of what you and your colleagues found to be most interesting in the field of diagnostic and ...

Home January 02, 2024
Home
Subscribe Now